| General Information | |
|---|---|
| ZINC ID | ZINC000040952361 |
| Molecular Weight (Da) | 420 |
| SMILES | CC(C)CCOc1cc(O)cc(OCCCCCCCCCCC(=O)NC2CC2)c1 |
| Molecular Formula | C25N1O4 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 120.775 |
| HBA | 4 |
| HBD | 2 |
| Rotatable Bonds | 17 |
| Heavy Atoms | 30 |
| LogP | 6.423 |
| Activity (Ki) in nM | 125.893 |
| Polar Surface Area (PSA) | 67.79 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | - |
| Plasma protein binding | 1.08083975 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 6 |
| Fraction csp3 | 0.72 |
| Ilogp | 4.99 |
| Xlogp3 | 6.78 |
| Wlogp | 5.92 |
| Mlogp | 3.36 |
| Silicos-it log p | 6.45 |
| Consensus log p | 5.5 |
| Esol log s | -5.67 |
| Esol solubility (mg/ml) | 0.000891 |
| Esol solubility (mol/l) | 0.00000212 |
| Esol class | Moderately |
| Ali log s | -8.01 |
| Ali solubility (mg/ml) | 0.0000041 |
| Ali solubility (mol/l) | 9.76E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -7.49 |
| Silicos-it solubility (mg/ml) | 0.0000136 |
| Silicos-it solubility (mol/l) | 3.25E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.05 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 2 |
| Veber number of violations | 1 |
| Egan number of violations | 1 |
| Muegge number of violations | 2 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.26 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.814 |
| Logd | 4.548 |
| Logp | 6.381 |
| F (20%) | 0.995 |
| F (30%) | 0.993 |
| Mdck | 2.55E-05 |
| Ppb | 0.9856 |
| Vdss | 0.818 |
| Fu | 0.0189 |
| Cyp1a2-inh | 0.289 |
| Cyp1a2-sub | 0.261 |
| Cyp2c19-inh | 0.831 |
| Cyp2c19-sub | 0.122 |
| Cl | 9.72 |
| T12 | 0.271 |
| H-ht | 0.257 |
| Dili | 0.062 |
| Roa | 0.12 |
| Fdamdd | 0.28 |
| Skinsen | 0.944 |
| Ec | 0.003 |
| Ei | 0.043 |
| Respiratory | 0.154 |
| Bcf | 0.975 |
| Igc50 | 5.142 |
| Lc50 | 4.833 |
| Lc50dm | 5.092 |
| Nr-ar | 0.045 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.839 |
| Nr-aromatase | 0.392 |
| Nr-er | 0.865 |
| Nr-er-lbd | 0.013 |
| Nr-ppar-gamma | 0.139 |
| Sr-are | 0.76 |
| Sr-atad5 | 0.198 |
| Sr-hse | 0.671 |
| Sr-mmp | 0.938 |
| Sr-p53 | 0.439 |
| Vol | 459.455 |
| Dense | 0.913 |
| Flex | 1.8 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 2 |
| Qed | 0.305 |
| Synth | 2.3 |
| Fsp3 | 0.72 |
| Mce-18 | 25.674 |
| Natural product-likeness | -0.236 |
| Alarm nmr | 1 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |